Cutler Group’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $20K | Sell |
2,600
-13,200
| -84% | -$1.62M | 0.01% | 1015 |
|
|
2023
Q4 | $159K | Sell |
15,800
-6,300
| -29% | -$604K | 0.01% | 852 |
|
|
2023
Q3 | $468K | Buy |
22,100
+4,500
| +26% | +$509K | 0.05% | 443 |
|
|
2023
Q2 | $339K | Sell |
17,600
-11,800
| -40% | -$1.52M | 0.05% | 432 |
|
|
2023
Q1 | $278K | Buy |
29,400
+27,100
| +1,178% | +$3.52M | 0.03% | 546 |
|
|
2022
Q4 | $13K | Buy |
2,300
+100
| +5% | +$11.6K | ﹤0.01% | 2541 |
|
|
2022
Q3 | $23K | Sell |
2,200
-9,900
| -82% | -$998K | ﹤0.01% | 2519 |
|
|
2022
Q2 | $74K | Buy |
12,100
+5,800
| +92% | +$427K | 0.01% | 1648 |
|
|
2022
Q1 | $83K | Sell |
6,300
-9,300
| -60% | -$712K | ﹤0.01% | 1838 |
|
|
2021
Q4 | $264K | Buy |
15,600
+11,000
| +239% | +$940K | 0.01% | 1118 |
|
|
2021
Q3 | $189K | Buy |
4,600
+800
| +21% | +$61.6K | 0.01% | 1407 |
|
|
2021
Q2 | $235K | Sell |
3,800
-1,800
| -32% | -$136K | 0.01% | 1243 |
|
|
2021
Q1 | $424K | Sell |
5,600
-42,000
| -88% | -$3.88M | 0.02% | 819 |
|
|
2020
Q4 | $343K | Buy |
47,600
+39,500
| +488% | +$5.85M | 0.02% | 809 |
|
|
2020
Q3 | $217K | Sell |
8,100
-7,600
| -48% | -$1.15M | 0.01% | 875 |
|
|
2020
Q2 | $210K | Buy |
15,700
+2,100
| +15% | +$286K | 0.01% | 852 |
|
|
2020
Q1 | $599K | Sell |
13,600
-7,500
| -36% | -$857K | 0.03% | 501 |
|
|
2019
Q4 | $438K | Buy |
21,100
+12,000
| +132% | +$1.21M | 0.03% | 495 |
|
|
2019
Q3 | $507K | Sell |
9,100
-24,200
| -73% | -$2.86M | 0.05% | 353 |
|
|
2019
Q2 | $32K | Buy |
33,300
+23,700
| +247% | +$2.88M | ﹤0.01% | 1875 |
|
|
2019
Q1 | $96K | Sell |
9,600
-6,700
| -41% | -$861K | 0.01% | 1023 |
|
|
2018
Q4 | $174K | Sell |
16,300
-7,400
| -31% | -$925K | 0.02% | 714 |
|
|
2018
Q3 | $97K | Sell |
23,700
-10,300
| -30% | -$1.41M | 0.01% | 1214 |
|
|
2018
Q2 | $263K | Buy |
34,000
+28,100
| +476% | +$2.65M | 0.02% | 666 |
|
|
2018
Q1 | $29K | Sell |
5,900
-15,300
| -72% | -$1.02M | ﹤0.01% | 2026 |
|
|
2017
Q4 | $21K | Sell |
21,200
-44,100
| -68% | -$2.34M | ﹤0.01% | 2527 |
|
|
2017
Q3 | $178K | Buy |
65,300
+27,400
| +72% | +$1.1M | 0.01% | 1249 |
|
|
2017
Q2 | $252K | Buy |
37,900
+18,100
| +91% | +$589K | 0.01% | 1107 |
|
|
2017
Q1 | $298K | Sell |
19,800
-277,000
| -93% | -$8.57M | 0.01% | 912 |
|
|
2016
Q4 | $4.38M | Sell |
296,800
-260,500
| -47% | -$10.5M | 0.16% | 105 |
|
|
2016
Q3 | $1.1M | Sell |
557,300
-31,000
| -5% | -$937K | 0.05% | 297 |
|
|
2016
Q2 | $9.76M | Buy |
588,300
+435,300
| +285% | +$8.06M | 0.5% | 19 |
|
|
2016
Q1 | $1.99M | Buy |
153,000
+36,900
| +32% | +$645K | 0.13% | 121 |
|
|
2015
Q4 | $364K | Buy |
+116,100
| New | +$3.76M | 0.02% | 790 |
|
Other funds holding SRPT
ACA
FCM
Cutler Group's SRPT Position: Q1 2024 in Review
Cutler Group reduced its Sarepta Therapeutics (SRPT) stake by 63% in Q1 2024, selling an estimated $1.43M and leaving 6,900 shares worth $893K. The position accounts for 0.29% of the portfolio, ranked #77.
Cutler Group first reported a position in SRPT in Q4 2015 and has held it in 32 quarters since. The position peaked at $3.93M in Q3 2016. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.
- Cutler Group held 6,900 shares of Sarepta Therapeutics worth $893K as of Q1 2024.
- Cutler Group sold 11,634 Sarepta Therapeutics shares in Q1 2024, an estimated $1.43M.
- Sarepta Therapeutics made up 0.29% of Cutler Group's portfolio in Q1 2024, its #77 holding.
- Cutler Group first reported a position in Sarepta Therapeutics in Q4 2015 and has held it in 32 quarters since.
- Cutler Group's Sarepta Therapeutics position peaked at $3.93M in Q3 2016.
- 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.
Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.